RecruitingChemotherapy Induced Neuropathic PainChemotherapy Induced Pain NeuropathyChemotherapy Induced Pain

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Eligible age

18+ yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.

Sponsor: Dogwood Therapeutics Inc.

You may qualify if…

✓ Male or female patients aged ≥18 years.
✓ Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
✓ Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.

You may not qualify if…

✕ Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.
✕ Patients who have received HAL at any time prior to screening.